Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial

This tutorial provides a step-by-step guide to performing cost-effectiveness analysis using a multi-state modeling approach. Alongside the tutorial, we provide easy-to-use functions in the statistics package R. We argue that this multi-state modeling approach using a package such as R has advantages over approaches where models are built in a spreadsheet package. In particular, using a syntax-based approach means there is a written record of what was done and the calculations are transparent. Reproducing the analysis is straightforward as the syntax just needs to be run again. The approach can be thought of as an alternative way to build a Markov decision-analytic model, which also has the option to use a state-arrival extended approach. In the state-arrival extended multi-state model, a covariate that represents patients’ history is included, allowing the Markov property to be tested. We illustrate the building of multi-state survival models, making predictions from the models and assessing fits. We then proceed to perform a cost-effectiveness analysis, including deterministic and probabilistic sensitivity analyses. Finally, we show how to create 2 common methods of visualizing the results—namely, cost-effectiveness planes and cost-effectiveness acceptability curves. The analysis is implemented entirely within R. It is based on adaptions to functions in the existing R package mstate to accommodate parametric multi-state modeling that facilitates extrapolation of survival curves.

[1]  Thomas Faunce,et al.  Decision-analytical modelling in health-care economic evaluations , 2008, The European Journal of Health Economics.

[2]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[3]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[4]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[6]  Hein Putter,et al.  mstate: An R Package for the Analysis of Competing Risks and Multi-State Models , 2011 .

[7]  H. Akaike A new look at the statistical model identification , 1974 .

[8]  Andrew Briggs,et al.  An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.

[9]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[10]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  Jan A M Raaijmakers,et al.  Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  Richard Grieve,et al.  Extrapolation of Survival Data in Cost-effectiveness Analyses , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[14]  Mark Sculpher,et al.  Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  Sarah Hancock,et al.  FLUDARABINE AS FIRST LINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA , 2003 .

[16]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[17]  Hein Putter,et al.  The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models , 2010, Comput. Methods Programs Biomed..

[18]  M. Connock,et al.  Cautions Regarding the Fitting and Interpretation of Survival Curves , 2011, PharmacoEconomics.

[19]  Elisabeth Fenwick,et al.  Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation , 2006, BMC Health Services Research.